Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
MYGN's Cash to Debt is ranked higher than
98% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.88 vs. MYGN: No Debt )
Ranked among companies with meaningful Cash to Debt only.
MYGN' s Cash to Debt Range Over the Past 10 Years
Min: 39.25  Med: No Debt Max: No Debt
Current: No Debt
Equity to Asset 0.85
MYGN's Equity to Asset is ranked higher than
88% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.58 vs. MYGN: 0.85 )
Ranked among companies with meaningful Equity to Asset only.
MYGN' s Equity to Asset Range Over the Past 10 Years
Min: 0.73  Med: 0.88 Max: 0.94
Current: 0.85
0.73
0.94
Interest Coverage No Debt
MYGN's Interest Coverage is ranked higher than
97% of the 127 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 83.10 vs. MYGN: No Debt )
Ranked among companies with meaningful Interest Coverage only.
MYGN' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
F-Score: 8
Z-Score: 8.49
M-Score: -2.59
WACC vs ROIC
0.96%
22.47%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating margin (%) 22.12
MYGN's Operating margin (%) is ranked higher than
90% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.48 vs. MYGN: 22.12 )
Ranked among companies with meaningful Operating margin (%) only.
MYGN' s Operating margin (%) Range Over the Past 10 Years
Min: -30.37  Med: 35.81 Max: 39.24
Current: 22.12
-30.37
39.24
Net-margin (%) 16.61
MYGN's Net-margin (%) is ranked higher than
89% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.51 vs. MYGN: 16.61 )
Ranked among companies with meaningful Net-margin (%) only.
MYGN' s Net-margin (%) Range Over the Past 10 Years
Min: -22.25  Med: 22.63 Max: 42
Current: 16.61
-22.25
42
ROE (%) 17.21
MYGN's ROE (%) is ranked higher than
86% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.35 vs. MYGN: 17.21 )
Ranked among companies with meaningful ROE (%) only.
MYGN' s ROE (%) Range Over the Past 10 Years
Min: -11.85  Med: 18.28 Max: 30.71
Current: 17.21
-11.85
30.71
ROA (%) 15.00
MYGN's ROA (%) is ranked higher than
95% of the 212 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.30 vs. MYGN: 15.00 )
Ranked among companies with meaningful ROA (%) only.
MYGN' s ROA (%) Range Over the Past 10 Years
Min: -10.72  Med: 16.98 Max: 28.73
Current: 15
-10.72
28.73
ROC (Joel Greenblatt) (%) 112.91
MYGN's ROC (Joel Greenblatt) (%) is ranked higher than
94% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -10.22 vs. MYGN: 112.91 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MYGN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -199.02  Med: 251.31 Max: 362.64
Current: 112.91
-199.02
362.64
Revenue Growth (3Y)(%) 11.70
MYGN's Revenue Growth (3Y)(%) is ranked higher than
73% of the 141 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.80 vs. MYGN: 11.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
MYGN' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 1.6  Med: 20.1 Max: 31.4
Current: 11.7
1.6
31.4
EBITDA Growth (3Y)(%) -2.50
MYGN's EBITDA Growth (3Y)(%) is ranked lower than
56% of the 123 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.80 vs. MYGN: -2.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
MYGN' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -10.2  Med: 12.15 Max: 48.5
Current: -2.5
-10.2
48.5
EPS Growth (3Y)(%) -1.10
MYGN's EPS Growth (3Y)(%) is ranked higher than
50% of the 117 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.10 vs. MYGN: -1.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
MYGN' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -17  Med: 3.3 Max: 67.9
Current: -1.1
-17
67.9
» MYGN's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-11-03)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

MYGN Guru Trades in Q3 2015

Paul Tudor Jones 11,274 sh (New)
Jim Simons 856,600 sh (+33.89%)
Ken Fisher 89,775 sh (+1.96%)
Mario Gabelli 25,000 sh (unchged)
First Pacific Advisors Sold Out
Chuck Royce 2,271,668 sh (-19.54%)
» More
Q4 2015

MYGN Guru Trades in Q4 2015

RS Investment Management 1,998,910 sh (New)
Joel Greenblatt 196,364 sh (New)
Paul Tudor Jones 21,386 sh (+89.69%)
Jim Simons 949,600 sh (+10.86%)
Ken Fisher 89,775 sh (unchged)
Mario Gabelli 25,000 sh (unchged)
Chuck Royce 1,414,898 sh (-37.72%)
» More
Q1 2016

MYGN Guru Trades in Q1 2016

RS Investment Management 2,178,740 sh (+9.00%)
Jim Simons 1,034,800 sh (+8.97%)
Paul Tudor Jones 22,391 sh (+4.70%)
Joel Greenblatt 201,527 sh (+2.63%)
Ken Fisher 89,783 sh (+0.01%)
Mario Gabelli 25,000 sh (unchged)
Chuck Royce 1,284,698 sh (-9.20%)
» More
Q2 2016

MYGN Guru Trades in Q2 2016

Lee Ainslie 93,870 sh (New)
First Eagle Investment 368,980 sh (New)
Joel Greenblatt 360,830 sh (+79.05%)
Jim Simons 1,332,300 sh (+28.75%)
Ken Fisher 92,236 sh (+2.73%)
Mario Gabelli 25,000 sh (unchged)
RS Investment Management Sold Out
Chuck Royce 937,498 sh (-27.03%)
Paul Tudor Jones 14,167 sh (-36.73%)
» More
» Details

Insider Trades

Latest Guru Trades with MYGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:NAS:AXDX, NAS:KANG, NAS:ABAX, NAS:ALOG, NAS:AFFX, NAS:GHDX, NAS:FMI, NAS:VIVO, NAS:EXAS, NAS:NEOG, NAS:QDEL, NAS:NVDQ, NAS:NEO, NYSE:ARA, NAS:NTRA, OTCPK:BMLIF, NAS:INCR, NAS:BEAT, NAS:NRCIA, NAS:SRDX » details
Traded in other countries:MYD.Germany,
Myriad Genetics Inc is a molecular diagnostic company. It develops and markets novel predictive medicine, personalized medicine and prognostic medicine tests. It also provides physicians with information to solve unmet medical needs.

Myriad Genetics Inc is a molecular diagnostic company, engaged in making a difference in patients lives through the discovery and commercialization of transformative tests which assess a persons risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. The Company's business segments include: research, molecular diagnostics and companion diagnostics. The research segment is engaged in the discovery of genes related to common diseases and includes corporate services such as finance, human resources, legal, and information technology. The molecular diagnostics segment provides testing that is designed to assess an individuals risk for developing disease later in life, identify a patients likelihood of responding to drug therapy and guide a patients dosing to ensure optimal treatment, or assess a patients risk of disease progression and disease recurrence. The companion diagnostics segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries. The Company offers nine commercial molecular diagnostic tests, including six predictive medicine tests, two personalized medicine tests, and one prognostic medicine test. The Company markets these tests through its sales force of approximately 400 people in the United States. It also markets BRACAnalysis, COLARIS, COLARIS AP, and Prolaris tests through its European sales force. The Companys competitors include other molecular diagnostic companies, diagnostic reference laboratories, large multi-national healthcare companies, and universities and other research institutions. The Company has 234 patents as well as patent applications in the United States and foreign countries. The patents and patent applications cover diagnostic biomarkers, genes, proteins, gene expression signatures, antibodies, primers, probes, assays, disease-associated genetic mutations and single-nucleotide polymorphisms, methods for determining genetic predisposition, methods for disease diagnosis, methods for determining disease progression, methods for correlation claims, and methods for disease treatment, and general molecular diagnostic techniques. The Companys U.S. patents relating to BRACAnalysis, COLARIS, COLARIS AP, MELARIS, PREZEON, PANEXIA and TruCulture also have related foreign issued patents in countries, including in Europe, Canada, Japan, Australia and New Zealand, claiming similar subject matter and having similar expiration dates. The services that the Company provides are regulated by federal, state and foreign governmental authorities.

Guru Investment Theses on Myriad Genetics Inc

Chuck Royce Comments on Myriad Genetics - Oct 08, 2014

Six equity sectors made net contributions to first-half returns, with Health Care out in front, driven in large part by the terrific results for molecular diagnostic company Myriad Genetics (MYGN), which was among the portfolio’s five largest detractors in 2013 when we substantially increased our position. The company specializes in genetic testing for cancer and ended last year facing increased competition, particularly in breast cancer screening tests, and some still unresolved reimbursement issues that remained under federal review at the end of December. It was also facing skepticism from some quarters about the fallout from a June 2013 Supreme Court decision that genes could not be patented. Our take was that neither the high court ruling nor the increased competition would hurt the firm’s long-term health. We see the quality of its predictive tests as the industry’s gold standard, so we were quite pleased to see it continue to execute successfully (and profitably), as well as make a savvy acquisition of Crescendo Bioscience, in the first half. The acquisition diversifies Myriad’s already promising pipeline. It was the Fund’s largest holding at the end of June.

From Chuck Royce (Trades, Portfolio)’s Royce Premier Fund Second Quarter 2014 Manager Commentary.

Check out Chuck Royce latest stock trades

Ratios

vs
industry
vs
history
P/E(ttm) 12.63
MYGN's P/E(ttm) is ranked higher than
86% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.60 vs. MYGN: 12.63 )
Ranked among companies with meaningful P/E(ttm) only.
MYGN' s P/E(ttm) Range Over the Past 10 Years
Min: 9.06  Med: 19.45 Max: 63.15
Current: 12.63
9.06
63.15
Forward P/E 19.61
MYGN's Forward P/E is ranked higher than
62% of the 42 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.74 vs. MYGN: 19.61 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 12.63
MYGN's PE(NRI) is ranked higher than
86% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.47 vs. MYGN: 12.63 )
Ranked among companies with meaningful PE(NRI) only.
MYGN' s PE(NRI) Range Over the Past 10 Years
Min: 9.06  Med: 18.54 Max: 40.65
Current: 12.63
9.06
40.65
Price/Owner Earnings (ttm) 17.00
MYGN's Price/Owner Earnings (ttm) is ranked higher than
79% of the 58 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.42 vs. MYGN: 17.00 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
MYGN' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 9.71  Med: 22.93 Max: 113.28
Current: 17
9.71
113.28
P/B 1.99
MYGN's P/B is ranked higher than
76% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.47 vs. MYGN: 1.99 )
Ranked among companies with meaningful P/B only.
MYGN' s P/B Range Over the Past 10 Years
Min: 1.88  Med: 3.72 Max: 8.23
Current: 1.99
1.88
8.23
P/S 2.09
MYGN's P/S is ranked higher than
67% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.27 vs. MYGN: 2.09 )
Ranked among companies with meaningful P/S only.
MYGN' s P/S Range Over the Past 10 Years
Min: 1.97  Med: 4.87 Max: 14.31
Current: 2.09
1.97
14.31
PFCF 9.81
MYGN's PFCF is ranked higher than
87% of the 61 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.45 vs. MYGN: 9.81 )
Ranked among companies with meaningful PFCF only.
MYGN' s PFCF Range Over the Past 10 Years
Min: 7.62  Med: 17 Max: 142.72
Current: 9.81
7.62
142.72
POCF 9.51
MYGN's POCF is ranked higher than
80% of the 80 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.96 vs. MYGN: 9.51 )
Ranked among companies with meaningful POCF only.
MYGN' s POCF Range Over the Past 10 Years
Min: 7.22  Med: 15.89 Max: 43.64
Current: 9.51
7.22
43.64
EV-to-EBIT 7.97
MYGN's EV-to-EBIT is ranked higher than
88% of the 94 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.20 vs. MYGN: 7.97 )
Ranked among companies with meaningful EV-to-EBIT only.
MYGN' s EV-to-EBIT Range Over the Past 10 Years
Min: -102.5  Med: 9.8 Max: 44
Current: 7.97
-102.5
44
EV-to-EBITDA 6.88
MYGN's EV-to-EBITDA is ranked higher than
87% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 16.73 vs. MYGN: 6.88 )
Ranked among companies with meaningful EV-to-EBITDA only.
MYGN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -161.3  Med: 9.4 Max: 38.5
Current: 6.88
-161.3
38.5
PEG 2.05
MYGN's PEG is ranked higher than
68% of the 37 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. MYGN: 2.05 )
Ranked among companies with meaningful PEG only.
MYGN' s PEG Range Over the Past 10 Years
Min: 0.47  Med: 1.08 Max: 3.43
Current: 2.05
0.47
3.43
Shiller P/E 17.59
MYGN's Shiller P/E is ranked higher than
90% of the 29 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 42.43 vs. MYGN: 17.59 )
Ranked among companies with meaningful Shiller P/E only.
MYGN' s Shiller P/E Range Over the Past 10 Years
Min: 16.5  Med: 49.13 Max: 2553
Current: 17.59
16.5
2553
Current Ratio 4.35
MYGN's Current Ratio is ranked higher than
75% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.43 vs. MYGN: 4.35 )
Ranked among companies with meaningful Current Ratio only.
MYGN' s Current Ratio Range Over the Past 10 Years
Min: 2.58  Med: 5.22 Max: 17.26
Current: 4.35
2.58
17.26
Quick Ratio 3.82
MYGN's Quick Ratio is ranked higher than
75% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. MYGN: 3.82 )
Ranked among companies with meaningful Quick Ratio only.
MYGN' s Quick Ratio Range Over the Past 10 Years
Min: 2.58  Med: 5.22 Max: 17.26
Current: 3.82
2.58
17.26
Days Inventory 70.59
MYGN's Days Inventory is ranked higher than
58% of the 165 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 88.85 vs. MYGN: 70.59 )
Ranked among companies with meaningful Days Inventory only.
MYGN' s Days Inventory Range Over the Past 10 Years
Min: 22.14  Med: 48.49 Max: 73.56
Current: 70.59
22.14
73.56
Days Sales Outstanding 44.41
MYGN's Days Sales Outstanding is ranked higher than
73% of the 160 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 64.52 vs. MYGN: 44.41 )
Ranked among companies with meaningful Days Sales Outstanding only.
MYGN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 38.41  Med: 46.88 Max: 72.25
Current: 44.41
38.41
72.25
Days Payable 48.96
MYGN's Days Payable is ranked lower than
59% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 60.15 vs. MYGN: 48.96 )
Ranked among companies with meaningful Days Payable only.
MYGN' s Days Payable Range Over the Past 10 Years
Min: 48.96  Med: 80.13 Max: 280.85
Current: 48.96
48.96
280.85

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 5.00
MYGN's 3-Year Average Share Buyback Ratio is ranked higher than
98% of the 129 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.80 vs. MYGN: 5.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MYGN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -13.6  Med: -6.5 Max: 5.9
Current: 5
-13.6
5.9

Valuation & Return

vs
industry
vs
history
Price/Net Cash 56.76
MYGN's Price/Net Cash is ranked lower than
91% of the 64 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.94 vs. MYGN: 56.76 )
Ranked among companies with meaningful Price/Net Cash only.
MYGN' s Price/Net Cash Range Over the Past 10 Years
Min: 3.83  Med: 9.54 Max: 80.53
Current: 56.76
3.83
80.53
Price/Net Current Asset Value 8.17
MYGN's Price/Net Current Asset Value is ranked higher than
51% of the 117 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.50 vs. MYGN: 8.17 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
MYGN' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 3.22  Med: 6.27 Max: 26.95
Current: 8.17
3.22
26.95
Price/Tangible Book 4.58
MYGN's Price/Tangible Book is ranked higher than
57% of the 154 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.65 vs. MYGN: 4.58 )
Ranked among companies with meaningful Price/Tangible Book only.
MYGN' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.68  Med: 3.71 Max: 19.86
Current: 4.58
1.68
19.86
Price/Projected FCF 0.57
MYGN's Price/Projected FCF is ranked higher than
96% of the 69 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.04 vs. MYGN: 0.57 )
Ranked among companies with meaningful Price/Projected FCF only.
MYGN' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.57  Med: 1.27 Max: 20.87
Current: 0.57
0.57
20.87
Price/Median PS Value 0.43
MYGN's Price/Median PS Value is ranked higher than
85% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.05 vs. MYGN: 0.43 )
Ranked among companies with meaningful Price/Median PS Value only.
MYGN' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.43  Med: 1.15 Max: 8.51
Current: 0.43
0.43
8.51
Price/Peter Lynch Fair Value 2.18
MYGN's Price/Peter Lynch Fair Value is ranked higher than
54% of the 24 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.27 vs. MYGN: 2.18 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
MYGN' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.7  Med: 1.64 Max: 3.09
Current: 2.18
0.7
3.09
Price/Graham Number 1.60
MYGN's Price/Graham Number is ranked higher than
74% of the 69 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.27 vs. MYGN: 1.60 )
Ranked among companies with meaningful Price/Graham Number only.
MYGN' s Price/Graham Number Range Over the Past 10 Years
Min: 1.04  Med: 2.27 Max: 3.35
Current: 1.6
1.04
3.35
Earnings Yield (Greenblatt) (%) 12.56
MYGN's Earnings Yield (Greenblatt) (%) is ranked higher than
95% of the 205 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.00 vs. MYGN: 12.56 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MYGN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 2.3  Med: 8.85 Max: 22.7
Current: 12.56
2.3
22.7
Forward Rate of Return (Yacktman) (%) 14.43
MYGN's Forward Rate of Return (Yacktman) (%) is ranked higher than
69% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.43 vs. MYGN: 14.43 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
MYGN' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -19.9  Med: 3.8 Max: 29.4
Current: 14.43
-19.9
29.4

More Statistics

Revenue (TTM) (Mil) $753.7
EPS (TTM) $ 1.71
Beta-0.09
Short Percentage of Float38.72%
52-Week Range $19.10 - 46.24
Shares Outstanding (Mil)69.13

Analyst Estimate

Jun17 Jun18 Jun19
Revenue (Mil $) 752 793 844
EPS ($) 1.18 1.40 1.45
EPS w/o NRI ($) 1.18 1.40 1.45
EPS Growth Rate
(3Y to 5Y Estimate)
1.41%
Dividends Per Share ($)
» More Articles for MYGN

Headlines

Articles On GuruFocus.com
Chuck Royce Reduces Several Positions in 4th Quarter Feb 05 2016 
Chuck Royce Comments on Myriad Genetics Oct 08 2014 
Chuck Royce’s Royce Premier Fund Second Quarter 2014 Manager Commentary Oct 08 2014 
Why I Bought Myriad Genetics (MYGN) Apr 28 2014 
Scott Black, Delphi Management Recommends Stocks Nov 19 2013 
Surfing for Billionaire Bargains Sep 22 2013 
Baron Funds Comments on Myriad Genetics Inc. Jun 06 2013 
RS Investments' Value Fund First Quarter 2012 Mutual Fund Commentary Apr 17 2012 
Chuck Royce Buys Hawkins Inc., Myriad Genetics, and Fairchild Semiconductor Jul 07 2011 
Myriad Genetics Inc. Reports Operating Results (10-Q) May 05 2010 

More From Other Websites
Myriad to Present New myRisk Hereditary Cancer Data Further Demonstrating the Benefits of Gene Panel... Sep 26 2016
Myriad to Present New myRisk Hereditary Cancer Data Further Demonstrating the Benefits of Gene Panel... Sep 26 2016
5 Stocks to Trade for Big Breakout Gains Sep 23 2016
ETF’s with exposure to Myriad Genetics, Inc. : September 21, 2016 Sep 21 2016
Myriad Genetics' TruCulture Study Results Favorable Sep 12 2016
ETF’s with exposure to Myriad Genetics, Inc. : September 9, 2016 Sep 09 2016
Myriad RBM's TruCulture® and Gene Expression Profiling Characterizes Immune Responses in Landmark... Sep 07 2016
Myriad RBM’s TruCulture® and Gene Expression Profiling Characterizes Immune Responses in Landmark... Sep 07 2016
Myriad Genetics Adds Assurex Health, Grows in Neuroscience Sep 06 2016
MYRIAD GENETICS INC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Creation... Sep 01 2016
Myriad Genetics Completes Acquisition of Assurex Health Sep 01 2016
Myriad Genetics Completes Acquisition of Assurex Health Sep 01 2016
Myriad Genetics to Present at the 2016 Morgan Stanley Global Healthcare Conference Aug 30 2016
Assurex Health CEO Gina Drosos to speak at Bizwomen Breakfast Aug 30 2016
ETF’s with exposure to Myriad Genetics, Inc. : August 29, 2016 Aug 29 2016
EXCLUSIVE: Assurex Health buyer has a Cincinnati connection (Video) Aug 24 2016
Myriad Genetics, Inc. :MYGN-US: Earnings Analysis: 2016 By the Numbers : August 23, 2016 Aug 23 2016
MYRIAD GENETICS INC Financials Aug 20 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)